Daiichi Sankyo
Last updated Aug 1, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
74%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Breast Cancer
- FLT3 Inhibitor
- Cardiovascular
- Atherosclerosis
Highest priority development: FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (breast cancer) as AstraZeneca.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 74%
Active Signals
13
Investigate Priority
0
Opportunity Score
769
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorAug 1, 2026Score 68Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy
Oncology · Breast Cancer
- MonitorJun 24, 2026Score 65Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy
Oncology · NSCLC
- MonitorJun 17, 2026Score 65Ifinatamab Deruxtecan Receives Priority Review for ES-SCLC in the U.S.
Oncology · Small Cell Lung Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancerLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Withdrawn | Cancer Accelerated ApprovalsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancerModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves zidesamtinib for ROS1-positive non-small cell lung cancerModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Daiichi Sankyo right now?
- Which regulatory precedents should Daiichi Sankyo monitor in Oncology and Breast Cancer?
- Which pipeline programs should Daiichi Sankyo prioritize for competitive review?
- What signals require immediate investigation for Daiichi Sankyo?
- Summarize the strategic implications of recent developments for Daiichi Sankyo.
- Where is the greatest uncertainty in Daiichi Sankyo's competitive positioning?